L'Hospitalet de Llobregat

The trials here

What the 20 trials at this site are about, from their registry records.

Conditions

• Amyloidosis4 trials
• Chronic lymphocytic leukaemia2 trials
• Dermatomyositis and polymyositis (myositis)2 trials
• Endometrial cancer2 trials
• Lung cancer2 trials
• Prostate cancer2 trials
• Bladder cancer1 trial
• Cervical cancer1 trial
• Childhood cancers1 trial
• Chronic kidney disease1 trial
• Follicular lymphoma1 trial
• Head and neck cancer1 trial
• and 11 more

Phase

• Phase 38 trials
• Phase 1/24 trials
• Phase 22 trials
• Phase 11 trial
• Phase 2/31 trial

Status

• Not yet recruiting6 trials
• Active, not recruiting5 trials
• Recruiting4 trials
• Terminated3 trials
• Completed2 trials

Lead sponsor

• AstraZeneca17 trials
• Alexion Pharmaceuticals, Inc.3 trials

Running trials

• Not yet recruiting

  An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy

  NCT07789483· Phase 3· Alexion Pharmaceuticals, Inc.· Source

  Contact: Alexion Pharmaceuticals, Inc., Sponsor

• Recruiting

  An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

  NCT07720284· Phase 3· AstraZeneca· Source

• Recruiting

  Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  NCT07690436· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

  NCT07608354· Phase 2· AstraZeneca· Source

• Recruiting

  A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

  NCT07652658· Phase 2· AstraZeneca· Source

• Recruiting

  Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  NCT07590934· Phase 1/2· AstraZeneca· Source

• Recruiting

  AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  NCT07611110· Phase 3· AstraZeneca· Source

• Active, not recruiting

  A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

  NCT06746116· Phase 3· AstraZeneca· Source

• Recruiting

  A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

  NCT06542250· Phase 1/2· AstraZeneca· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

  NCT06455449· Phase 3· AstraZeneca· Source

• Recruiting

  AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

  NCT06137144· Phase 1/2· AstraZeneca· Source

• Active, not recruiting

  Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

  NCT06183931· Phase 3· Alexion Pharmaceuticals, Inc.· Source

• Active, not recruiting

  Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

  NCT06109779· Phase 3· AstraZeneca· Source

• Recruiting

  PICAROS - Acalabrutinib RWE on 1L CLL in Spain

  NCT05999877· AstraZeneca· Source

• Recruiting

  A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

  NCT05123482· Phase 1/2· AstraZeneca· Source

  Contact: AstraZeneca Breast Cancer Study Locator Service

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• Prostate cancer2 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Heart failure1 recruiting
• Hodgkin lymphoma1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Lung cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Ovarian cancer1 recruiting

Closed trials

• Completed

  AZAHAR Study To Describe Anifrolumab in a Real-World Setting

  NCT06626945· AstraZeneca· Source

• Terminated

  An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/or Metastatic Breast Cancer

  NCT05592483· AstraZeneca· Source

• Terminated

  Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis

  NCT04999020· Phase 2/3· Alexion Pharmaceuticals, Inc.· Source

• Terminated

  A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia

  NCT05056727· Phase 3· AstraZeneca· Source

• Completed

  First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

  NCT04504669· Phase 1· AstraZeneca· Source